Richard Bartram - 28 Jun 2021 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Financial Officer
Signature
/s/ Richard B. Bartram
Issuer symbol
ESPR
Transactions as of
28 Jun 2021
Net transactions value
$0
Form type
4
Filing time
30 Jun 2021, 16:27:08 UTC
Next filing
01 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ESPR Stock Option (right to buy) Award $0 +37,500 $0.000000 37,500 28 Jun 2021 Common Stock 37,500 $22.52 Direct F1
transaction ESPR Performance-based Restricted Stock Units Award $0 +26,400 $0.000000 26,400 28 Jun 2021 Common Stock 26,400 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be October 15, 2021.
F2 Each Performance-Based Restricted Stock Unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock.
F3 These shares were issued in connection with a reward of performance-based restricted stock units that will vest only if performance goals are achieved over a two-year period beginning July 1, 2021. The actual number of units (if any) received under this award will depend on continued employment and actual performance over the two-year performance period.